NHERF1/EBP50 in breast cancer: Clinical perspectives

Antonia Bellizzi, Andrea Malfettone, Rosa A. Cardone, Anita Mangia

Research output: Contribution to journalArticlepeer-review


Na+/H+ exchanger regulatory factor 1 (NHERF1) is a postsynaptic density 95/disc-large/zona occludens (PDZ) domain-containing protein that recruits membrane receptors/transporters and cytoplasmic signaling proteins into functional complexes. NHERF1 expression has been demonstrated to be altered in breast cancer, but its role in mammary cancerogenesis and progression remains still undefined. In this paper, we review what is known on the pathological role and the potential clinical application of NHERF1 protein in breast cancer. Recent evidence shows that an increased cytoplasmic expression of NHERF1 suggests a key role of its localization/compartmentalization in defining cancerogenesis, progression, and invasion. NHERF1 overexpression is associated with increasing tumor cytohistological grade, aggressive clinical behavior, unfavorable prognosis, and increased tumor hypoxia. Moreover, NHERF1 co-localizes with the oncogenic receptor HER2/neu in HER2/neu-overexpressing carcinoma and in distant metastases. These data make NHERF1 also a potential candidate of clinical relevance for anti-HER2/neu therapy.

Original languageEnglish
Pages (from-to)86-90
Number of pages5
JournalBreast Care
Issue number2
Publication statusPublished - Apr 2010


  • Breast cancer
  • HER2/neu
  • NHERF1/EBP50

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'NHERF1/EBP50 in breast cancer: Clinical perspectives'. Together they form a unique fingerprint.

Cite this